Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Jul 28, 2025.

Back to dashboard

Medicare AdvantageCoverageLow impact

MA08.183, Zenocutuzumab-zbco (Bizengri®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Jul 28, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new Medicare Advantage policy MA08.183 has been established for Zenocutuzumab-zbco (Bizengri®), a pharmacy benefit drug. This creates new coverage guidelines for this specific medication under Medicare Advantage plans.

Action Required

Action needed

By July 28, 2025: Billing team should review the full policy details at the source URL to understand coverage criteria and any prior authorization requirements for Zenocutuzumab-zbco (Bizengri®). Update pharmacy benefit protocols if this medication is prescribed by providers in the practice.

Related policy hubs

Independence Blue Cross policies Oncology Hematology